Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

IMPORTANCE Approximately one-third of patients with peripheral artery disease experience intermittent claudication, with consequent loss of quality of life. OBJECTIVE To determine the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and quality of life in patients with claudication. DESIGN, SETTING, AND PATIENTS Randomized, double-blind, placebo-controlled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] years), initiated in May 2008 and completed in August 2011 and conducted at 3 hospitals in Australia. INTERVENTION Patients were randomized to receive 10 mg/d of ramipril (n = 106) or matching placebo (n = 106) for 24 weeks. MAIN OUTCOME MEASURES Maximum and pain-free walking times were recorded during a standard treadmill test. The Walking Impairment Questionnaire (WIQ) and Short-Form 36 Health Survey (SF-36) were used to assess walking ability and quality of life, respectively. RESULTS At 6 months, relative to placebo, ramipril was associated with a 75-second (95% CI, 60-89 seconds) increase in mean pain-free walking time (P < .001) and a 255-second (95% CI, 215-295 seconds) increase in maximum walking time (P < .001). Relative to placebo, ramipril improved the WIQ median distance score by 13.8 (Hodges-Lehmann 95% CI, 12.2-15.5), speed score by 13.3 (95% CI, 11.9-15.2), and stair climbing score by 25.2 (95% CI, 25.1-29.4) (P < .001 for all). The overall SF-36 median Physical Component Summary score improved by 8.2 (Hodges-Lehmann 95% CI, 3.6-11.4; P = .02) in the ramipril group relative to placebo. Ramipril did not affect the overall SF-36 median Mental Component Summary score. CONCLUSIONS AND RELEVANCE Among patients with intermittent claudication, 24-week treatment with ramipril resulted in significant increases in pain-free and maximum treadmill walking times compared with placebo. This was associated with a significant increase in the physical functioning component of the SF-36 score. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00681226.

[1]  J. Stevens,et al.  Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638) , 2013, British Journal of Surgery.

[2]  E. Henriksen,et al.  The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle , 2013, Molecular and Cellular Endocrinology.

[3]  J. W. Stevens,et al.  Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication , 2012, The British journal of surgery.

[4]  J. Ehrman,et al.  Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication Exercise Versus Endoluminal Revascularization (CLEVER) Study , 2012, Circulation.

[5]  S. Rajagopalan,et al.  Effect of Hypoxia-Inducible Factor-1&agr; Gene Therapy on Walking Performance in Patients With Intermittent Claudication , 2011, Circulation.

[6]  Sanjay Rajagopalan,et al.  Medical management of the patient with intermittent claudication. , 2011, Cardiology clinics.

[7]  John B Carlin,et al.  American Journal of Epidemiology Practice of Epidemiology Strategies for Multiple Imputation in Longitudinal Studies , 2022 .

[8]  R. Pande,et al.  A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication , 2010, Vascular medicine.

[9]  M. B. Jensen,et al.  Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[10]  A. LaCroix,et al.  Angiotensin‐Converting Enzyme Inhibitor Use and Incident Frailty in Women Aged 65 and Older: Prospective Findings from the Women's Health Initiative Observational Study , 2009, Journal of the American Geriatrics Society.

[11]  A. Dyer,et al.  Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. , 2008, Journal of vascular surgery.

[12]  R. Pande,et al.  A randomized trial of iloprost in patients with intermittent claudication , 2008, Vascular medicine.

[13]  W. Kirch,et al.  Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study , 2007, Angiology.

[14]  M. Mcmurdo,et al.  Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial , 2007, Canadian Medical Association Journal.

[15]  Xiao-Hua Zhou,et al.  Multiple imputation: review of theory, implementation and software , 2007, Statistics in medicine.

[16]  T. Henry,et al.  Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. , 2007, American heart journal.

[17]  C. Reid,et al.  Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease , 2006, Annals of Internal Medicine.

[18]  B. Lévy,et al.  Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Luigi Ferrucci,et al.  Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. , 2004, JAMA.

[20]  J. Illnait,et al.  Effects of Policosanol and Ticlopidine in Patients with Intermittent Claudication: A Double-Blinded Pilot Comparative Study , 2004, Angiology.

[21]  J. Williamson,et al.  Antihypertensive Medications and Differences in Muscle Mass in Older Persons: The Health, Aging and Body Composition Study , 2004, Journal of the American Geriatrics Society.

[22]  Mark A. Creager,et al.  Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.

[23]  P. Pagano,et al.  Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats , 2003, Journal of hypertension.

[24]  M. Aschwanden,et al.  Reproducibility of constant-load treadmill testing with various treadmill protocols and predictability of treadmill test results in patients with intermittent claudication. , 2002, Journal of vascular surgery.

[25]  J. Williamson,et al.  Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study , 2002, The Lancet.

[26]  P. Lehert,et al.  Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. , 2002, International angiology : a journal of the International Union of Angiology.

[27]  S. Takeshita,et al.  Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. , 2001, Cardiovascular research.

[28]  L. Sharma,et al.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. , 2001, JAMA.

[29]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[30]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[31]  D. Dawson,et al.  A comparison of cilostazol and pentoxifylline for treating intermittent claudication. , 2000, The American journal of medicine.

[32]  B. Besse,et al.  Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. , 2000, Circulation.

[33]  B. Besse,et al.  Oral Beraprost Sodium, a Prostaglandin I2 Analogue, for Intermittent Claudication A Double-Blind, Randomized, Multicenter Controlled Trial , 2000 .

[34]  D. Guez,et al.  The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. , 2000, Microvascular research.

[35]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[36]  K. Jaeger,et al.  Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol , 1999, Vascular medicine.

[37]  D. Dawson,et al.  A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. , 1999, Archives of internal medicine.

[38]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[39]  J. Schaper,et al.  Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. , 1999, Journal of molecular and cellular cardiology.

[40]  J. Isner,et al.  Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. , 1999, Circulation.

[41]  J. Crouse,et al.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Volterrani,et al.  Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. , 1998, Circulation.

[43]  Y. Nakaya,et al.  Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. , 1998, Diabetes.

[44]  J. A. Herd,et al.  Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. , 1998, Journal of vascular surgery.

[45]  J. Wood,et al.  Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin‐angiotensin system , 1997, Journal of hypertension.

[46]  K. Swedberg,et al.  Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. , 1996, European heart journal.

[47]  M. Shichiri,et al.  Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway , 1996, Diabetologia.

[48]  R. Bretzel,et al.  ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group. , 1994, The American journal of medicine.

[49]  A. Breckenridge,et al.  Double-Blind Comparison of Captopril with Nifedipine in Hypertension Complicated by Intermittent Claudication , 1992, Angiology.

[50]  D. Sacks,et al.  Peripheral Arterial Doppler Ultrasonography: Diagnostic Criteria , 1992, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[51]  G. Ciuffetti,et al.  Physical Training and Antiplatelet Treatment in Stage II Peripheral Arterial Occlusive Disease: Alone or Combined? , 1991, Angiology.

[52]  Sumner Ds,et al.  The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. , 1969 .

[53]  I. Chetter,et al.  Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. , 2011, International journal of surgery.

[54]  M. Cesari,et al.  ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2010, Journal of the American Medical Directors Association.

[55]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[56]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[57]  H. Lithell,et al.  Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. , 1999, Blood pressure.

[58]  J. Steiner,et al.  Exercise training improves functional status in patients with peripheral arterial disease. , 1996, Journal of vascular surgery.

[59]  A. Smit,et al.  The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. , 1994, VASA. Zeitschrift fur Gefasskrankheiten.

[60]  A. Nicolaides,et al.  The effect of enalapril on leg muscle blood flow in patients with claudication. , 1990, International angiology : a journal of the International Union of Angiology.

[61]  D. Sumner,et al.  The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. , 1969, Surgery.